81 results about "Inositol monophosphate" patented technology

The invention relates to a vitamin feed additive premix for sea fish, and belongs to the technical field of feed additives for fish culture. The vitamin feed additive premix is prepared by uniformly mixing vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B 12, nicotinic acid, folic acid, calcium pantothenate, biotin, inositol, VC (vitamin C) phosphate ester and zeolite powder according to a certain percentage ratio and further adding into feed according to the proportion of 0.5%-1%. The vitamin feed additive premix disclosed by the invention has the following advantages: (1) the vitamin feed additive premix can be used during the whole culture cycle; (2) the adding amount in the feed for the sea fish is 0.5%-1%; (3) the immunity of fresh water fish can be effectively enhanced and the survival rate is improved; (4) the vitamin feed additive premix disclosed by the invention has no adverse effects on palatability of the feed; and (5) raw material sources used by the vitamin feed additive premix disclosed by the invention are stable, the price is low, and the production process is simple.

The present invention relates to inositol phosphate derivatives, in which the inositol phosphate is substituted with one or two reactive groups G or one or two conjugated substances or molecules M, said reactive group(s) G or said substance(s) or molecule(s) M being linked to IP1 via a linkage group L, M being chosen from the following group: a tracer, an immunogen, a member of a binding partner pair, a solid support.Application: tools allowing the study of the inositol phosphate cycle and therefore, indirectly, the study of seven transmembrane domain receptors coupled to phospholipase C, receptors having a tyrosine kinase activity, and in general enzymes involved in the variations of the intracellular concentration of IP1.

The invention provides compounds of formula (I) in which R1, R2, R3, R4 and R5 are independently selected from hydrogen and chromogenic substituents, and X is selected from the group consisting of hydroxyl; OR6 wherein R6 is selected from the group consisting of C1-C4 alkyl; and O-Me+ wherein Me+ is a cation derived from an organic or inorganic base. A preferred species of formula (I) is 4-Methylumbelliferyl myo-inositol-1-phosphate and salts thereof with an organic or inorganic base. The invention also provides fluorogenic methods for detecting various pathogenic bacteria, e.g., Listeria, Staphylococcus and Clostridium species, using substrates containing at least one formula (I) compound. A kit for detecting a phosphatidyl-inositol-specific phospholipase C enzyme as an indication of bacterial activity is disclosed.

The invention relates to a method for preparing inositol through enzymic catalysis. The method comprises the following steps: performing enzyme-catalyzed conversion on a polysaccharide or an oligosaccharide which takes glucose as a unit to obtain glucose-1-phosphate; performing enzyme-catalyzed conversion on the glucose-1-phosphate to obtain glucose-6-phosphate; performing enzyme-catalyzed conversion on the glucose-6-phosphate to obtain inositol-1-phosphate; performing enzyme-catalyzed conversion on the inositol-1-phosphate to obtain inositol. The invention also provides an inositol product which is prepared according to the method. According to the method, the conversion efficiency of the inositol is effectively improved; moreover, a production process is simple, pollution-free, and low in production cost.

The invention discloses a road paving material utilizing ceramic waste and construction waste and a preparation method thereof, and relates to the field of utilization of ceramic waste. Road paving materials use 30-50 parts of Portland cement, 50-90 parts of ceramic waste fine aggregate, 120-160 parts of construction waste coarse aggregate, 15-20 parts of zeolite powder, 1-10 parts of organic fiber, sodium sulfate 1~5 parts, 1~2 parts of water reducer, 1~3 parts of polyurea gelling agent, 0.5~1 part of inositol phosphate, 20~40 parts of water as raw materials. The invention utilizes ceramic waste and construction waste to compound regenerated aggregate to solve the environmental pollution problem caused by ceramic waste and construction waste, and effectively mixes the regenerated aggregate with zeolite and organic fiber after esterification treatment to ensure that the concrete is While having sufficient strength, it can effectively solidify heavy metal ions in ceramic waste and construction waste, and effectively prevent secondary pollution to the environment.

The invention relates to the field of bioengineering, in particular to an inositol-3-phosphate synthase mutant and application of the inositol-3-phosphate synthase mutant in construction of corynebacterium glutamicum for high yield of glutamine. It is found that after 84th-site serine of inositol-3-phosphate synthase is mutated into other amino acids, the glutamine production capacity of corynebacterium glutamicum can be enhanced in corynebacterium glutamicum. Compared with a wild strain without mutation, the corynebacterium glutamicum has the advantages that the glutamine production capacity of the corynebacterium glutamicum is enhanced, the glutamine yield is increased to 30.7 g / L from 28.5 g / L, the acid production is increased by 7.7%, and screening and construction of a glutamine high-yield strain are facilitated.

The present disclosure relates to a method for preparing myo-inositol using myo-inositol monophosphate synthase consisting of an amino acid sequence of SEQ ID NO: 1 and / or myo-inositol monophosphate phosphatase consisting of an amino acid sequence of SEQ ID NO: 3.

The invention features methods for identifying compounds that modulate the activity of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) Inhibitors of PI5P4K can be used in, for example, the treatment or prevention of cell proliferation dis orders (e.g., the prevention of tumor cell growth in p53 mutated cancers).

The invention discloses a preparation method of high-purity sugammadex sodium. The high-purity sugammadex sodium is prepared from inositol phosphate and derivatives thereof. The specific process comprises the following steps of adding a specific type of protective agent into a crude sugammadex sodium product, and performing recrystallizing under the protection of inert gas to obtain a pure sugammadex sodium product, wherein the protective agent is selected from the inositol phosphate and the derivatives thereof, such as inositol hexaphosphate and salts or esters thereof, partial degradation products of the inositol hexaphosphate, such as inositol pentaphosphate, inositol tetraphosphate, inositol triphosphate, inositol diphosphate and inositol monophosphate, and one or a mixture of two or more of the above-mentioned substances and salts or esters thereof in any proportion. The method is simple and convenient to operate, high in product purity, good in safety, few in anaphylactic reaction, good in economical efficiency and more suitable for industrial production.

The invention relates to a kit for diagnosing / measuring lithium by utilizing the technologies of the enzymic colorimetry and the enzyme linked immunosorbent assay, wherein, the activity of the kit can be inhibited by lithium. The invention further relates to a method, a principle and the composition and the components of a reagent for measuring the concentration of lithium, and belongs to the technical field of medical / industrial / environmental inspection and measurement. The main components of the kit include a buffer solution, reduced coenzyme, magnesium chloride, inositol-1-phosphate, an oxaloacetic acid, a pyruvic acid, inositol-1-phosphatase, phosphoenolpyruvate carboxykinase, malic dehydrogenase and a stabilizer. Through mixing a check sample and a lithium sample respectively with the reagent by a certain volume ratio, a series of enzymatic reactions occur, then the reactant is placed under an ultraviolet / visible light analyzer, the degree / velocity of the decrease in absorbance at 340 nm of the dominant wavelength is detected, and the difference in the degree / velocity of the decrease between the check sample and lithium sample is compared, thereby measuring the concentration of lithium.

The invention relates to the field of enzymatic catalytic preparation of inositol, in particular to an enzymatic preparation method for producing inositol by complete phosphorolysis of cellulose. According to the preparation method of inositol, pretreated cellulose (the main component is fiber polysaccharide) is used as a substrate for the enzyme catalytic reaction; and cellulose polysaccharide phosphorylase, cellobiose phosphorylase, polyphosphate glucokinase, phosphoglucomutase, inositol-1-phosphate synthase and inositol monophosphatase are adopted to catalyze complete phosphorolysis of cellulose polysaccharide into inositol. By optimizing the multienzyme reaction process and controlling the reaction temperature in stages, the conversion efficiency of the substrate and the inositol yieldare significantly improved, and the reaction time is shortened. The technical method realizes the complete phosphorolysis of the cellulose substrate, and can also be used for other in-vitro multi-enzyme reaction systems to catalyze cellulose polysaccharide for production of hydrogen, electricity or other bio-based chemicals.

The invention discloses application of effective inhibitor of III-type phosphatidylinositol phosphate kinase in preparing drug for treating or preventing influenza virus infection. Research results prove that the effective inhibitor, namely a small molecule compound: 6-amino-N-[3-[4-(4-morpholinyl)pyridine[3', 2':4, 5] furan [3, 2-d] pyrimidine-2-base] phenyl]3-pyridine carboxamide can inhibit copying of influenza A virus subtype H1N1 amantadine drug-tolerant strain, influenza A virus subtype H6N6 strain, influenza A virus subtype H7N8 strain and influenza B virus in a dosage-dependent mannerwithin a nontoxic range, thereby having great wide-spectrum influenza virus resistant activity. Therefore, the small molecular compound is safe, efficient and little in toxic and side effect during clinical treatment of influenza.

The invention relates to a dunaliellaviridis myo-Inositol-1-phosphatesynthase gene (DvMIPS), and a protein coded thereby and application thereof. The gene is a DNA (Deoxyribonucleic Acid) sequence shown as SEQ ID NO1. According to the invention, the myo-Inositol-1-phosphatesynthase gene DvMIPS is separated from dunaliellaviridis for the first time; and conversion of yeast cells shows that the gene not only has the phosphatesynthase function, but also has the application value of improving the biological salt tolerance character.

The invention provides an engineering bacterium for producing inositol. The engineering bacterium comprises a host bacterium and a plasmid vector transferred into the host bacterium; a gene for encoding inositol-1-phosphate synthase is introduced into the plasmid vector, or a gene for encoding inositol-1-phosphate synthase and a gene for overexpressing and encoding inositol monophosphase are introduced into the plasmid vector at the same time. The invention also provides a construction method and application of the engineering bacterium for producing inositol. According to the engineering bacterium, endogenous enzyme is overexpressed while the exogenous enzyme is utilized, gene regulation and control are conducted in combination with RED recombination, the yield of inositol and the yield of a carbon source are increased step by step, and therefore rapid growth of a host and efficient production of inositol are achieved with sucrose, glucose, glycerol and other simple carbon sources as sources and through mutual coordination of production and growth.

Herein is disclosed a method of generating ascorbic acid from yeast transformed with a mannose epimerase. In a further embodiment, the yeast can be further transformed with a myoinositol phosphatase. In the method, the transformed yeast can produce L-ascorbic acid from D-glucose. The transformed yeast has been observed to have increased growth rate, cell density, or survival when cultured on appropriate media.

The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo.

The invention relates to a kit for diagnosing / measuring lithium by utilizing the technologies of the enzymic colorimetry and the enzyme linked immunosorbent assay, wherein, the activity of the kit can be inhibited by lithium. The invention further relates to a method, a principle and the composition and the components of a reagent for measuring the concentration of lithium, and belongs to the technical field of medical / industrial / environmental inspection and measurement. The main components of the kit include a buffer solution, coenzyme, magnesium chloride, inositol-1-phosphate, sucrose, inositol-1-phosphatase, sucrose phosphorylase, fructose dehydrogenase and a stabilizer. Through mixing a check sample and a lithium sample respectively with the reagent by a certain volume ratio, a series of enzymatic reactions occur, then the reactant is placed under an ultraviolet / visible light analyzer, the degree / velocity of the increase in absorbance at 340 nm of the dominant wavelength is detected, and the difference in the degree / velocity of the increase between the check sample and lithium sample is compared, thereby measuring the concentration of lithium.

The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.

The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and / or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg / kg to 9 mg / kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.

A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. The compound may be used for treating disorders related to unbalanced phosphatidylinositol phosphate cascade or signaling pathway. Diagnostic methods and methods for treating the disorders with therapeutic compounds or by gene therapy are also disclosed.